Early Access Program data supports robust efficacy and safety, reinforcing results from the pivotal ARES trial and strengthening …
Early Access Program data supports robust efficacy and safety, reinforcing results from the pivotal ARES trial and strengthening …
This approval adds a key anti-inflammatory eye drop to Amneal’s Affordable Medicines portfolio, with a commercial launch planned …
June 11 reveals critical progress across cell and gene therapies, metabolic disease drug research, and strategic industry partnerships …
June 10 sees robust momentum in biotechnology with novel therapeutic developments, advanced clinical trials, key industry events, and …
The FDA’s June 9 drug approvals bring new preventive options for infants at risk of RSV, innovative combination …
Significant biotech advancements and industry collaborations define early June with a focus on live biotherapeutics, liquid biopsies, and …
Early clinical successes, new research on immune toxicities, and expanding partnerships underscore the evolving landscape of cell and …
Adding atezolizumab to FOLFOX chemotherapy after surgery boosts disease-free survival in patients with surgically resected mismatch repair deficient …
Big pharma pursues targeted expansion while trials in radiopharmaceuticals and immunotherapy highlight the breadth of innovation across cancer, …
A large phase III study known as SERENA-6 is attracting wide attention for challenging the way resistance is …
Already a subscriber? Log in